X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT LTD. - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT LTD. GLENMARK PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 19.7 -18.5 - View Chart
P/BV x 3.5 2.0 175.8% View Chart
Dividend Yield % 0.3 0.0 15,494.7%  

Financials

 GLENMARK PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
WOCKHARDT LTD.
Mar-18
GLENMARK PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs9301,012 91.9%   
Low Rs517532 97.3%   
Sales per share (Unadj.) Rs322.6355.9 90.7%  
Earnings per share (Unadj.) Rs28.5-60.3 -47.3%  
Cash flow per share (Unadj.) Rs39.2-46.8 -83.8%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.30 21,327.9%  
Book value per share (Unadj.) Rs183.0257.8 71.0%  
Shares outstanding (eoy) m282.17110.63 255.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.2 103.4%   
Avg P/E ratio x25.4-12.8 -198.4%  
P/CF ratio (eoy) x18.5-16.5 -111.9%  
Price / Book Value ratio x4.03.0 132.1%  
Dividend payout %7.00 -42,316.6%   
Avg Mkt Cap Rs m204,20685,379 239.2%   
No. of employees `00013.76.3 219.3%   
Total wages/salary Rs m18,7189,371 199.8%   
Avg. sales/employee Rs Th6,636.86,295.0 105.4%   
Avg. wages/employee Rs Th1,364.71,498.3 91.1%   
Avg. net profit/employee Rs Th586.1-1,066.3 -55.0%   
INCOME DATA
Net Sales Rs m91,03139,369 231.2%  
Other income Rs m9141,202 76.0%   
Total revenues Rs m91,94540,571 226.6%   
Gross profit Rs m16,15418 88,272.1%  
Depreciation Rs m3,0191,495 201.9%   
Interest Rs m2,8562,555 111.8%   
Profit before tax Rs m11,193-2,830 -395.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m3,155257 1,227.5%   
Profit after tax Rs m8,039-6,669 -120.5%  
Gross profit margin %17.70 38,176.0%  
Effective tax rate %28.2-9.1 -310.3%   
Net profit margin %8.8-16.9 -52.1%  
BALANCE SHEET DATA
Current assets Rs m69,88733,796 206.8%   
Current liabilities Rs m32,87926,917 122.1%   
Net working cap to sales %40.717.5 232.7%  
Current ratio x2.11.3 169.3%  
Inventory Days Days8179 102.6%  
Debtors Days Days9389 104.8%  
Net fixed assets Rs m28,89239,664 72.8%   
Share capital Rs m282553 51.0%   
"Free" reserves Rs m51,35327,968 183.6%   
Net worth Rs m51,63528,522 181.0%   
Long term debt Rs m41,41821,731 190.6%   
Total assets Rs m125,95481,620 154.3%  
Interest coverage x4.9-0.1 -4,575.6%   
Debt to equity ratio x0.80.8 105.3%  
Sales to assets ratio x0.70.5 149.8%   
Return on assets %8.6-5.0 -171.6%  
Return on equity %15.6-23.4 -66.6%  
Return on capital %15.1-7.7 -196.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,3179,807 370.3%   
Fx outflow Rs m9,7201,789 543.4%   
Net fx Rs m26,5988,019 331.7%   
CASH FLOW
From Operations Rs m16,481684 2,408.0%  
From Investments Rs m-10,1336,302 -160.8%  
From Financial Activity Rs m-4,685-7,695 60.9%  
Net Cashflow Rs m1,770-664 -266.6%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades 370 Points Up; Hero MotoCorp & Tata Motors Gain Over 5%(12:30 pm)

Stock markets in India are presently trading higher following the outcome of assembly polls announced on Tuesday.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Dec 12, 2018 03:35 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - TTK HEALTHCARE COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS